STAT+: ‘We don’t unlearn’: What the pandemic has taught regulators about real-world data

During the pandemic, regulatory agencies deployed emergency measures left and right to speed care to patients.

Today, that’s leaving the health care industry, and especially younger digital startups, in a tricky spot. Companies have benefited from the reduced regulatory burden of the pandemic — but it’s unclear how long they’ll get to ride the gravy train. “What’s going to happen is the regulatory agencies are required to essentially go back to the way it was before,” said Amy Abernethy, former deputy principal commissioner and acting CIO at the FDA. “But we don’t unlearn.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.